Kintara Therapeutics, Inc. (KTRA)
| Previous close | 0.1572 |
| Open | 0.1565 |
| Bid | 0.1540 x 4600 |
| Ask | 0.1582 x 2200 |
| Day's range | 0.1499 - 0.1624 |
| 52-week range | 0.0810 - 5.6000 |
| Volume | |
| Avg. volume | 14,666,246 |
| Market cap | 6.098M |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.2200 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksKintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.
PR NewswireKintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, and TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and res
- PR Newswire
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer (CMBC) to include patients receiving pembrolizumab (KEYTRUDA®) for at least three months at screening.
